|
NL129025C
(OSRAM)
*
|
1965-04-29 |
|
|
|
|
US3542729A
(en)
*
|
1968-03-19 |
1970-11-24 |
Sankyo Co |
Stabilization of synthetic polymers
|
|
BE790675A
(fr)
*
|
1971-10-29 |
1973-04-27 |
Science Union & Cie |
Nouveaux derives de l'oxa-1 diaza-3,8 spiro (4,5) decane
|
|
US4244961A
(en)
*
|
1978-10-26 |
1981-01-13 |
Syntex (U.S.A.) Inc. |
1-Oxa-3,8-diazaspiro[4.5]decan-2-ones antihypertensive agents
|
|
US4255432A
(en)
*
|
1979-09-06 |
1981-03-10 |
Syntex (U.S.A.) Inc. |
8-[2-3-Indolyl)ethyl]-1-oxa-3-,8-diazaspiro[4.5]decan-2-ones, pharmaceutical compositions thereof and methods of use thereof
|
|
ES517622A0
(es)
*
|
1982-11-23 |
1983-12-16 |
Faes |
Procedimiento de preparacion de un nuevo espirodecano.
|
|
YU150489A
(sh)
*
|
1989-08-10 |
1992-12-21 |
W.L. Gore & Co. Gmbh. |
Uređaj za ispitivanje odevnih predmeta na nepromočivost
|
|
HU204054B
(en)
*
|
1989-08-10 |
1991-11-28 |
Richter Gedeon Vegyeszet |
Process for producing new 1-oxa-2-oxo-8-azaspiro(4,5)decane derivatives and pharmaceutical compositions comprising same
|
|
FR2666583B1
(fr)
*
|
1990-09-06 |
1994-09-09 |
Adir |
Nouveaux derives du spiro [4.5] decane, leur procede de preparation et leurs compositions pharmaceutiques les renfermant.
|
|
FR2734265B1
(fr)
*
|
1995-05-17 |
1997-06-13 |
Adir |
Nouveaux composes spiro heterocycliques, leur procede de preparation et les compositions pharmaceutiques les contenant
|
|
US6982251B2
(en)
*
|
2000-12-20 |
2006-01-03 |
Schering Corporation |
Substituted 2-azetidinones useful as hypocholesterolemic agents
|
|
EP1413331B1
(en)
*
|
2001-01-26 |
2007-10-03 |
Schering Corporation |
Combinations of the peroxisome proliferator-activated receptor (PPAR) activator fenofibrate with sterol absorption inhibitor ezetimibe for vascular indications
|
|
US7071181B2
(en)
*
|
2001-01-26 |
2006-07-04 |
Schering Corporation |
Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
|
|
EP1785144A3
(en)
*
|
2001-01-26 |
2007-05-23 |
Shering Corporation |
Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications
|
|
DK1385548T3
(da)
*
|
2001-01-26 |
2007-09-10 |
Schering Corp |
Kombinationer af sterolabsorptionsinhibitor(er) med (et eller flere) kardiovaskulære midler til behandling af vaskulære tilstande
|
|
KR20040025890A
(ko)
*
|
2001-01-26 |
2004-03-26 |
쉐링 코포레이션 |
혈관성 질환을 치료하기 위한 스테롤 흡수 억제제와 혈액조절제의 조합물
|
|
MXPA03006727A
(es)
*
|
2001-01-26 |
2003-10-24 |
Schering Corp |
Combinaciones de acido nicotinico y derivados del mismo con inhibidor(es) de la absorcion de los esteroles, y tratamiento para indicaciones vasculares.
|
|
KR20070120617A
(ko)
*
|
2001-01-26 |
2007-12-24 |
쉐링 코포레이션 |
치환된 아제티딘온 화합물을 포함하는 약제학적 조성물
|
|
ATE345792T1
(de)
*
|
2001-05-25 |
2006-12-15 |
Schering Corp |
Verwendung von mit azetidinon substituierten derivaten bei der behandlung der alzheimer- krankheit
|
|
DE10130020A1
(de)
*
|
2001-06-25 |
2003-12-04 |
Gruenenthal Gmbh |
Substituierte 1-Oxa-2,8-diaza-spiro[4.5]dec-2-en-derivate
|
|
DE10146275A1
(de)
|
2001-09-18 |
2003-04-24 |
Gruenenthal Gmbh |
Kombination ausgewählter Opioide mit Muscarin-Antagonisten zur Therapie der Harninkontinenz
|
|
US7056906B2
(en)
*
|
2001-09-21 |
2006-06-06 |
Schering Corporation |
Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
|
|
US7053080B2
(en)
*
|
2001-09-21 |
2006-05-30 |
Schering Corporation |
Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
|
|
US20030119808A1
(en)
*
|
2001-09-21 |
2003-06-26 |
Schering Corporation |
Methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects
|
|
DE60216300T2
(de)
*
|
2001-09-21 |
2007-06-28 |
Schering Corp. |
Behandlung von xanthom mittels azetidinon-derivate als hemmer der sterol absorption
|
|
NZ531060A
(en)
*
|
2001-09-21 |
2006-06-30 |
Schering Corp |
Methods for treating or preventing vascular inflammation using sterol absorption inhibitor(s)
|
|
JP3835763B2
(ja)
|
2002-08-19 |
2006-10-18 |
ファイザー・プロダクツ・インク |
増殖亢進疾患のための組み合わせ治療
|
|
CA2504916A1
(en)
*
|
2002-11-06 |
2004-05-27 |
Schering Corporation |
Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
|
|
DE602004018617D1
(de)
|
2003-03-07 |
2009-02-05 |
Schering Corp |
Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
|
|
CA2517573C
(en)
*
|
2003-03-07 |
2011-12-06 |
Schering Corporation |
Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
|
|
MXPA05009503A
(es)
|
2003-03-07 |
2005-10-18 |
Schering Corp |
Compuestos de azetidinona sustituidos, formulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
|
|
US7459442B2
(en)
|
2003-03-07 |
2008-12-02 |
Schering Corporation |
Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
|
|
US20050037063A1
(en)
*
|
2003-07-21 |
2005-02-17 |
Bolton Anthony E. |
Combined therapies
|
|
JP2007510659A
(ja)
*
|
2003-11-05 |
2007-04-26 |
シェーリング コーポレイション |
脂質調節剤および置換アゼチジノンの組み合わせならびに血管状態の処置
|
|
JP2007522160A
(ja)
|
2004-02-10 |
2007-08-09 |
エフ.ホフマン−ラ ロシュ アーゲー |
ケモカインccr5受容体モジュレーター
|
|
US20060063803A1
(en)
*
|
2004-09-23 |
2006-03-23 |
Pfizer Inc |
4-Amino substituted-2-substituted-1,2,3,4-tetrahydroquinoline compounds
|
|
GT200600381A
(es)
|
2005-08-25 |
2007-03-28 |
|
Compuestos organicos
|
|
US7741317B2
(en)
|
2005-10-21 |
2010-06-22 |
Bristol-Myers Squibb Company |
LXR modulators
|
|
US7888376B2
(en)
|
2005-11-23 |
2011-02-15 |
Bristol-Myers Squibb Company |
Heterocyclic CETP inhibitors
|
|
US8383660B2
(en)
|
2006-03-10 |
2013-02-26 |
Pfizer Inc. |
Dibenzyl amine compounds and derivatives
|
|
US7919506B2
(en)
|
2006-03-10 |
2011-04-05 |
Pfizer Inc. |
Dibenzyl amine compounds and derivatives
|
|
ATE547394T1
(de)
|
2006-12-01 |
2012-03-15 |
Bristol Myers Squibb Co |
N-((3-benzyl)-2,2-(bis-phenyl)-propan-1- aminderivate als cetp-hemmer für die behandlung von atherosklerose und herz-kreislauf- erkrankungen
|
|
JP2010522707A
(ja)
*
|
2007-03-29 |
2010-07-08 |
エフ.ホフマン−ラ ロシュ アーゲー |
抗ウイルス性複素環化合物
|
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
|
ES2559319T3
(es)
|
2007-06-04 |
2016-02-11 |
Synergy Pharmaceuticals Inc. |
Agonistas de guanilato cliclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
|
|
CA2726917C
(en)
|
2008-06-04 |
2018-06-26 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
|
WO2010009319A2
(en)
|
2008-07-16 |
2010-01-21 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
|
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
|
CN102766147B
(zh)
*
|
2012-08-03 |
2015-07-15 |
无锡药兴医药科技有限公司 |
一种芬司匹利及其氢卤酸盐的制备方法
|
|
CA2905438A1
(en)
|
2013-03-15 |
2014-09-25 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase and their uses
|
|
AU2014235209B2
(en)
|
2013-03-15 |
2018-06-14 |
Bausch Health Ireland Limited |
Guanylate cyclase receptor agonists combined with other drugs
|
|
JP2016516804A
(ja)
|
2013-04-17 |
2016-06-09 |
ファイザー・インク |
心血管疾患を治療するためのn−ピペリジン−3−イルベンズアミド誘導体
|
|
WO2014197720A2
(en)
|
2013-06-05 |
2014-12-11 |
Synergy Pharmaceuticals, Inc. |
Ultra-pure agonists of guanylate cyclase c, method of making and using same
|
|
GB201416346D0
(en)
*
|
2014-09-16 |
2014-10-29 |
Shire Internat Gmbh |
Spirocyclic derivatives
|
|
WO2016055901A1
(en)
|
2014-10-08 |
2016-04-14 |
Pfizer Inc. |
Substituted amide compounds
|
|
HRP20241674T1
(hr)
|
2019-01-18 |
2025-02-14 |
Astrazeneca Ab |
6'-[[(1s,3s)-3-[[5-(difluormetoksi)-2-pirimidinil]amino]ciklopentil]amino][1(2h),3'-bipiridin]-2-on kao inhibitor pcsk9 i postupci njegove upotrebe
|